Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M
Department V of Oncology, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Br J Cancer. 1999 Mar;79(9-10):1553-63. doi: 10.1038/sj.bjc.6690248.
To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene expression was moderately associated with an increase in the IMD (r2 = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD (r2 = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively).
为评估血管生成因子与实际人类胰腺癌是否具有临床相关性,我们采用免疫组织化学方法研究了40例胰腺癌的瘤内微血管密度(IMD)以及PD-ECGF、VEGF蛋白表达情况。我们还使用逆转录聚合酶链反应(RT-PCR)研究了PD-ECGF和VEGF基因表达。在所研究的40例胰腺癌中,30例癌(75.0%)被评估为PD-ECGF阳性,10例癌(25.0%)被确定为PD-ECGF阴性。相比之下,27例癌(67.5%)被评估为VEGF阳性,而13例癌(32.5%)为VEGF阴性。VEGF基因表达与IMD增加呈中度相关(r2 = 0.181,P = 0.006),但未发现PD-ECGF基因表达与IMD之间存在显著关系(r2 = 0.093,P = 0.059)。然而,PD-ECGF和VEGF均呈阳性表达的肿瘤具有更高的IMD(P = 0.027)。免疫组织化学结果与定量RT-PCR结果高度一致。高血管组的中位生存时间显著短于低血管组(P < 0.0001)。在根据PD-ECGF和VEGF基因表达比较生存情况时,PD-ECGF表达阳性患者的中位生存时间显著短于PD-ECGF表达阴性患者(P = 0.040)。此外,VEGF表达阳性患者的中位生存时间显著短于VEGF表达阴性患者(P = 0.048)。然而,Cox多因素分析表明,IMD和VEGF表达是胰腺癌患者各种临床病理变量的独立预后因素(分别为P = 0.0021和P = 0.0443)。